presentation biomerica covid19 - micro-medical...2019 may 2020 international for use outside the usa...
Post on 23-Jan-2021
1 Views
Preview:
TRANSCRIPT
2019
May 2020
International
Biomerica COVID-19 May 2020 rev 1.pptxFor use outside the USA - these statements have not been evaluated by the FDA
We are an experienced manufacturer of FDA
cleared products
We contract manufacture for 2 multinational
pharma companies, Bio-Rad and other
leading organizations
World Class Scientific Advisory Board –
Members of the ROME Foundation
Device manufacturing experience with over
20 products
Two FDA registered manufacturing facilities
Who We Are
Major
customers
2For use outside the USA - these statements have not been evaluated by the FDA
3
› Immunoassay test kit for the
qualitative detection of IgG
and IgM antibodies specific
to SARS-CoV-2 in human
capillary whole blood, serum,
or plasma specimens.
For use outside the USA - these statements have not been evaluated by the FDA
4
Does not require lab processingNo equipment required
Quick, simple to useConvenient. Read by eye. 10 minutes to result
Patient management
Fast decision-making
Reliable and accurateCE Mark. Combined Sensitivity: 100%, Specificity: 95%
For use outside the USA - these statements have not been evaluated by the FDA
References: [1] Vashist, S.K. In Vitro Diagnostic Assays for COVID-19: Recent Advances and Emerging Trends. Diagnostics 2020, 10, 202 [3] Ria Lassaunière1, Anders Frische1, Zitta B. Harboe2,3, Alex C.Y. Nielsen4, Anders Fomsgaard1, Karen A. Krogfelt1,5,
Charlotte S. Jørgensen1*
5
› SARS-CoV-2 is a large
positive-sense single-
stranded ribonucleic acid
(RNA) virus that comprises of
four structural proteins;
nucleocapsid protein (NP)
that holds the viral RNA,
spike protein (SP), envelope
protein (EP), and membrane
protein (MP), that create the
viral envelope[1].
SARS-CoV-2 schematic[1]
For use outside the USA - these statements have not been evaluated by the FDA
References: World Health Organisation. Questions and Answers on coronaviruses (COVID-19), M 2020, viewed 04 May 2020, <https://www.who.int/news-room/q-a-detail/q-a-coronaviruses>
6
› The World Health
Organization (WHO) termed
the disease, coronavirus
disease 2019 (COVID-19),
and the causative virus,
severe acute respiratory
syndrome coronavirus 2
(SARS-CoV-2).
› Most common symptoms:
› Fever.
› Dry cough.
› Tiredness
› Less common symptoms:
› Aches and pains
› Diarrhea
› Loss of taste and smell
For use outside the USA - these statements have not been evaluated by the FDA
References: [1] Wei Zhang, Rong-Hui Du, Bei Li, Xiao-Shuang Zheng, Xing-Lou Yang, Ben Hu, Yan-Yi Wang, Geng-Fu Xiao, Bing Yan, Zheng-Li Shi & Peng Zhou (2020) Molecular and serological investigation of 2019-nCoV infected patients: implication of
multiple shedding routes, Emerging Microbes & Infections, 9:1, 386-389, DOI: 10.1080/22221751.2020.1729071
7
To determine who has been infected• Who can return to work – healthcare workers, emergency services, public health stakeholders• Surveillance• Epidemiology (seroprevalence)
Public Health • Social distancing strategy• ‘Immunity’ passports
To determine who is infected in conjunction with PCR[1]
• Who should be isolated
• Contact tracing
• Clinical management
For use outside the USA - these statements have not been evaluated by the FDA
References: Table Reproduced From: Patel R, Babady E, Theel ES, Storch GA, Pinsky BA, St. George K, Smith TC, Bertuzzi S. 2020. Report from the American Society for Microbiology COVID-19 International Summit, 23 March 2020: Value of diagnostic testing for
SARS–CoV-2/COVID-19. mBio 11:e00722-20. https://doi.org/10.1128/mBio.00722-20.
8
› Testing for COVID-19 is
broadly split into Tests for
Viral RNA and Serology.
For use outside the USA - these statements have not been evaluated by the FDA
9For use outside the USA - these statements have not been evaluated by the FDA
References: [1] Patel R, Babady E, Theel ES, Storch GA, Pinsky BA, St. George K, Smith TC, Bertuzzi S. 2020. Report from the American Society for Microbiology COVID-19 International Summit, 23 March 2020: Value of diagnostic testing for SARS–CoV-2/COVID-
19. mBio 11:e00722-20. https://doi.org/10.1128/mBio.00722-20. [2] Li, Z, Yi, Y, Luo, X, et al. Development and clinical application of a rapid IgM‐IgG combined antibody test for SARS‐CoV‐2 infection diagnosis. J Med Virol. 2020; 1–
7. https://doi.org/10.1002/jmv.25727. [3] Liu L, Liu W, Zheng Y, et al. A preliminary study on serological assay for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 238 admitted hospital patients [published online ahead of print, 2020 May
18]. Microbes Infect. 2020;10.1016/j.micinf.2020.05.008. doi:10.1016/j.micinf.2020.05.008
10
› Serology looks at the
development of an antibody
response to infection which
can be host dependent and
take time. In the case of
SARS–CoV-2, early studies
suggest that the majority of
patients seroconvert between
7 and 11 days postexposure
to the virus, although some
patients may develop
antibodies sooner[1].
› For illustrative purposes only. Data from Liu et al. (2020) and Li et al. (2020)[2,3]
For use outside the USA - these statements have not been evaluated by the FDA
References: Prestidge, Marelize; Amoore, Zara. 2020. Purpose and Options for Testing for SARS-Cov2 (the COVID-19 Virus) : Considerations for World Bank Task Teams Managing COVID-19 Fast Track Facility Operations (English). Washington, D.C. : World Bank
Group. http://documents.worldbank.org/curated/en/145161586536712080/Purpose-and-Options-for-Testing-for-SARS-Cov2-the-COVID-19-Virus-Considerations-for-World-Bank-Task-Teams-Managing-COVID-19-Fast-Track-Facility-Operations
11
› It is proposed that there is a
place for viral RNA testing
and antibody detection when
accessible.
› In some countries and
settings this may not be
possible and antibody
detection may offer the best
cost-effective option for
identifying COVID-19
patients.
For use outside the USA - these statements have not been evaluated by the FDA
12
› Remove test strip from
cannister or test device from
foil pouch.
› Place test strip on test card or
test device on a level surface.
› Set timer for 10 minutes.
› Add 20 µl whole blood or 10 µl
serum/plasma.
› Read result and control line
after 10 minutes.
For use outside the USA - these statements have not been evaluated by the FDA
13
› Positive Results
› Negative Results
› Invalid Results
For use outside the USA - these statements have not been evaluated by the FDA
14
› The sensitivity and specificity of the BIOMERICA
COVID-19 IgG/IgM Rapid Test was calculated in
comparison with a commercial PCR (China-FDA,
EUA) (Novel Coronavirus 2019-nCov PCR Kit).
› Sensitivity of the BIOMERICA COVID-19
IgG/IgM is the percentage of patients correctly
identified as having a positive IgG/IgM
response when compared to a positive PCR
result.
› Specificity of the BIOMERICA COVID-19
IgG/IgM is the percentage of patients correctly
identified as having a negative IgG/IgM
response when compared to a negative PCR
result.
For use outside the USA - these statements have not been evaluated by the FDA
top related